Amylex’s CEO, Mr. Rogelio “Vonz” Santos, shares the journey and continuous researches of Amylex to develop a “new weapon” that can contribute in the fight against Alzheimer’s. The medical technology that was developed and studied for nearly two decades received the commercial approval by the Philippine Food and Drug Administration (FDA). BETACLEAR® is approved as a dialysate with enhanced beta-amyloid extraction properties.
The event was hosted by Lyceum Philippines University last April 2018. Mr. Santos discussed new insights in the field of Alzheimer’s research, the origins and concepts behind BETACLEAR®, and the research behind the link between Alzheimer’s and diabetes. He also discusses Amylex’s unique research and treatment strategy utilizing pathology intervention models to find better methods in potentially addressing Alzheimer’s at an earlier stage.
© 2022 Amylex. All Rights Reserved. Terms & Conditions Legal terms Services and Inquiries